Stacey M. Allen

Heidelberg, VIC, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma.

A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 04, 2025

Correction to: Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993.

Correction to: Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993.

Journal: European journal of nuclear medicine and molecular imaging
Published: August 26, 2024

Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993.

Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993.

Journal: European journal of nuclear medicine and molecular imaging
Published: December 03, 2023

Inhibition of EphA3 Expression in Tumour Stromal Cells Suppresses Tumour Growth and Progression.

Inhibition of EphA3 Expression in Tumour Stromal Cells Suppresses Tumour Growth and Progression.

Journal: Cancers
Published: August 03, 2023

MAIT Cells Promote Tumor Initiation, Growth, and Metastases via Tumor MR1.

MAIT Cells Promote Tumor Initiation, Growth, and Metastases via Tumor MR1.

Journal: Cancer discovery
Published: May 18, 2019

Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome.

Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome.

Journal: Oncoimmunology
Published: November 20, 2018

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.

Journal: Oncoimmunology
Published: June 12, 2018

Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23.

Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23.

Journal: Cancer immunology research
Published: February 06, 2018

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.

Journal: Oncoimmunology
Published: January 11, 2018

Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis.

Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis.

Journal: Oncoimmunology
Published: November 08, 2017

Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.

Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 02, 2017

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.

Journal: Cancer discovery
Published: May 22, 2016
Showing 1-12 of 20

Last Updated: 09/26/2026